Business Wire

How Dahua Technology Helps Prevent Forest Fires

18.5.2021 16:45:00 EEST | Business Wire | Press release

Share

It takes decades for trees to grow, yet only minutes for fires to destroy them. Forest fires are the type of natural disaster that strike with sudden destructiveness and are often difficult to control. That’s why working to prevent forest fires and the damage they cause to natural resources — as well as people’s property and sometimes human life — is a priority for Dahua Technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005588/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dahua Solution Safeguarding The Yarlung Zangbo Grand Canyon (Photo: Business Wire)

Over the years, Dahua Technology has developed and deployed capabilities for comprehensive technical support in forest and grassland fire monitoring as well as early warning, forecasting, rescue and post-disaster assessment with digital intelligence technology. Dahua’s technology fully integrates video perception systems with integrated sky and ground monitoring methods to form a strong "fire net" aimed at prevention and early, decisive intervention when needed.

The Yarlung Zangbo Grand Canyon is the largest and deepest canyon on earth. The terrain of the canyon forest area is complex, steep and deep, with precious and diverse vegetation ecological resources, and is very difficult to protect. Dahua Technology helped build a smart forest fire prevention monitoring system, safeguarding forests through digital technology. Based on thermal imaging technology, the system provides 360° long-distance monitoring and uninterrupted 7/24 protection, guarding the vast forests and lush mountains.

In Chibi City, Hubei, Dahua Technology built an integrated forest fire prevention system for Guantangyi Forest Farm. The system uses dual-spectral thermal imaging to detect fires in real time, links video feeds to command centers, and connects alarms on fire ranger’s handheld devices, through to a six-rotor UAV that monitors the situation from above. The seamless flow of information through this system enables forest rangers to rush to a target area with a patrol terminal in hand to conduct on-site command, fire search and rescue, and other first responder functions.

It takes integrated capabilities working together to save forests, and Dahua solutions make it possible. Dahua employees take special pride in being able to contribute to this mission; for example, “When I walked through many forested areas in the country, every time I was not only emotional, but also felt responsible. Dahua Technology has always been involved in forest fire prevention. In the future, the company will continue to use technology to protect the ecology and intelligence to guard a green future.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Vivid Gu
18969121820
PR_Global@dahuatech.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye